American Association for Cancer Research
Browse
00085472can161589-sup-166620_1_supp_3739669_qghjgq.doc (106 kB)

Supplementary Material and Methods from RB Loss Promotes Prostate Cancer Metastasis

Download (106 kB)
journal contribution
posted on 2023-03-31, 01:05 authored by Chellappagounder Thangavel, Ettickan Boopathi, Yi Liu, Alex Haber, Adam Ertel, Anshul Bhardwaj, Sankar Addya, Noelle Williams, Stephen J. Ciment, Paolo Cotzia, Jeffry L. Dean, Adam Snook, Chris McNair, Matt Price, James R. Hernandez, Shuang G. Zhao, Ruth Birbe, James B. McCarthy, Eva A. Turley, Kenneth J. Pienta, Felix Y. Feng, Adam P. Dicker, Karen E. Knudsen, Robert B. Den

Supplemental Methods and Material

Funding

Prostate Cancer Foundation

American Cancer Society

NIH

History

ARTICLE ABSTRACT

RB loss occurs commonly in neoplasia but its contributions to advanced cancer have not been assessed directly. Here we show that RB loss in multiple murine models of cancer produces a prometastatic phenotype. Gene expression analyses showed that regulation of the cell motility receptor RHAMM by the RB/E2F pathway was critical for epithelial–mesenchymal transition, motility, and invasion by cancer cells. Genetic modulation or pharmacologic inhibition of RHAMM activity was sufficient and necessary for metastatic phenotypes induced by RB loss in prostate cancer. Mechanistic studies in this setting established that RHAMM stabilized F-actin polymerization by controlling ROCK signaling. Collectively, our findings show how RB loss drives metastatic capacity and highlight RHAMM as a candidate therapeutic target for treating advanced prostate cancer. Cancer Res; 77(4); 982–95. ©2016 AACR.

Usage metrics

    Cancer Research

    Categories

    Keywords

    Cell CycleCDKs and CDK inhibitorsGenitourinary CancersProstate cancerOncogenes & Tumor SuppressorsRb and familyProgression, Invasion & MetastasisMetastasisMigration and invasion

    Licence

    CC BY

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC